AngioDynamics, Inc. (ANGO) Analysts See $0.21 EPS

June 14, 2018 - By Maria Brooks

AngioDynamics, Inc. (NASDAQ:ANGO) LogoInvestors sentiment increased to 1.46 in 2018 Q1. Its up 0.20, from 1.26 in 2017Q4. It is positive, as 17 investors sold AngioDynamics, Inc. shares while 40 reduced holdings. 25 funds opened positions while 58 raised stakes. 34.89 million shares or 2.93% more from 33.90 million shares in 2017Q4 were reported.
Regions Financial Corp, Alabama-based fund reported 500 shares. Fny Managed Accounts Llc holds 0% in AngioDynamics, Inc. (NASDAQ:ANGO) or 10 shares. Jpmorgan Chase And Company has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Jacobs Levy Equity Mngmt invested in 0.06% or 214,448 shares. Acadian Asset Llc reported 79,965 shares stake. Fort Washington Inv Advsr Inc Oh accumulated 1.03 million shares or 0.18% of the stock. Parkside Natl Bank And owns 37 shares or 0% of their US portfolio. Loomis Sayles & Company Limited Partnership has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Moreover, State Board Of Administration Of Florida Retirement System has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 35,168 shares. Great West Life Assurance Can reported 45,532 shares. Bnp Paribas Arbitrage Sa holds 13,079 shares or 0% of its portfolio. Heartland Advisors invested in 0.4% or 347,249 shares. Nordea Mgmt Ab holds 182,312 shares or 0.01% of its portfolio. Thomson Horstmann Bryant Inc reported 373,313 shares stake. Metropolitan Life Ins New York invested in 0% or 11,730 shares.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.21 EPS on July, 17.They anticipate $0.02 EPS change or 10.53 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.73M giving it 25.75 P/E if the $0.21 EPS is correct. After having $0.25 EPS previously, AngioDynamics, Inc.’s analysts see -16.00 % EPS growth. The stock increased 0.79% or $0.17 during the last trading session, reaching $21.63. About 106,900 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 30.75% since June 14, 2017 and is uptrending. It has outperformed by 18.18% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 3 analysts covering Angiodynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Angiodynamics had 5 analyst reports since January 5, 2018 according to SRatingsIntel. The rating was upgraded by Raymond James to “Outperform” on Tuesday, April 3. The rating was maintained by Canaccord Genuity with “Hold” on Thursday, March 29. The firm has “Hold” rating given on Thursday, January 4 by Canaccord Genuity. The firm has “Hold” rating given on Friday, January 5 by Craig Hallum. Canaccord Genuity maintained it with “Hold” rating and $17 target in Monday, April 2 report.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $796.08 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 600.83 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More news for AngioDynamics, Inc. (NASDAQ:ANGO) were recently published by: Benzinga.com, which released: “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” on June 01, 2018. Nasdaq.com‘s article titled: “Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience …” and published on May 29, 2018 is yet another important article.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: